Kailera Therapeutics, Inc.
KLRA
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.5B
Close$
$1.27
88.7% downside
Current Fair Value
88.7% downsideOvervalued by 88.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.50 Billion |
|---|---|
| Enterprise Value | $1.38 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.26 |
| Beta | 0.5 |
| Outstanding Shares | 102,226,608 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -6.6 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 1.13 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 25, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-1.01
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.06%▼ 99.35% |
|---|---|
| Total Invested | $680,563▼ 99.97% |
| Investors Holding | 4▼ 98.00% |
ESG Score
No data
About Kailera Therapeutics, Inc.
145 employees
CEO: Ronald C. Renaud Jr. Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tac...